A team of researchers from across five disciplines at MD Anderson recently published the largest prospective study on breast implant associated anaplastic large cell lymphoma (BIA-ALCL), shedding light on the best treatment for patients with this uncommon cancer.
“This study underscores the critical importance of a standard treatment approach with a multi-team evaluation,” says Mark Clemens, M.D., the senior author of the study...
Triple combination therapy kills glioblastoma in mice by putting an “eat me” signal to the immune system on the surface of the brain tumor...
Combining two immunotherapies caused tumor rejection in mouse models of pancreatic cancer and provided long-term immune memory that prevented...
Triple-negative breast cancer (TNBC) is an aggressive disease that makes up roughly 15% to 20% of breast cancer diagnoses. Standard chemotherapy works for about half of these patients. But there is a significant need for personalized options to improve outcomes for all patients.
Through the Breast Cancer Moon Shot®, MD Anderson is conducting an innovative clinical trial, called ARTEMIS, to develop personalized therapy approaches...
Surveying the landscape of T cell presence and activity across the lungs of patients treated for localized non-small cell lung cancer, researchers...
Cellular therapies have emerged as an effective new therapy for patients with certain types of cancer, and MD Anderson has played an important...
An immunotherapy used against advanced non-small cell lung cancer is being tested at MD Anderson for a different...
MD Anderson’s adoptive cell therapy (ACT) platform is advancing the next generation of cell-based immune therapies to bring innovative approaches...
Combining two types of immune checkpoint inhibitor fires up responses in T cells that are separate from those initiated by the two drugs individually...
Glioblastoma (GBM) is not among the most commonly diagnosed cancers in the U.S., but it can certainly be among the most devastating. Of the...